This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Surgical or radio-iodine treatment in thyrotoxicosis

Authoring team

Indications for radioiodine treatment include:

  • radio-iodine treatment
    • can be used as the first-line treatment for adults with Graves' disease, toxic adenoma, and toxic multinodular goitre.
      • should be considered as the preferred treatment for those
        • with severe Graves’ disease, especially young patients aged less than 40 years, men, and those with a large goitre
        • who are unlikely to achieve long term remission with antithyroid drugs
    • early use of radioiodine has been shown to be the cheapest long term strategy in managing Graves’ disease
    • a pragmatic fixed dose that results in euthryoidism or hypothyroidism in 70-90% of patients is recommended
    • treatment with optimal individual dose of radioiodine does not improve outcome
    • doses of 370 to 550 MBq for routine use in Graves’ disease is used in the UK (large goitres may need higher doses)
    • regular thyroid function tests should be carried out to detect radioiodine induced hypothyroidism early
    • release of preformed hormone may lead exacerbation of thyrotoxicosis (or even a thyroid storm being precipitated)
      • pre-treatment with thionamides (until euthyroid) is recommended to reduce the risk in patients with large goitres, severe thyrotoxicosis, ischaemic heart disease, heart failure, or arrhythmia
    • optimal outcome from radioiodine can be obtained by stopping methimazole or carbimazole at least a week before radioiodine therapy
      • if propylthiouracil is used, it should be stopped at least two weeks before radioiodine
    • absolute contraindications include:
      • pregnancy
      • breastfeeding
      • planning pregnancy
      • inability to comply with radiation safety recommendations
    • if biopsy of thyroid nodules indicates or are suspicious for cancer, radioiodine treatment is contraindicated
    • women of child-bearing age are advised to avoid pregnancy for six months after receiving radio-iodine treatment
    • the presence of Graves' ophthalmopathy is a relative contra-indication to radio-iodine therapy because it may deteriorate after radio-iodine treatment (1,2)

Thyroidectomy is the most effective and predictable treatment for Graves’ disease

  • total thyroidectomy is preferred over subtotal thyroidectomy since the frequency of successful outcomes are significantly higher in the former with no differences in the rate of complications
  • especially recommended for the following patients:
    • large goitres (cosmetically undesirable) or low uptake of radioactive iodine (or both)
    • suspected or documented thyroid cancer
    • moderate-to-severe ophthalmopathy, for which radioactive iodine therapy is contraindicated
    • a preference for surgery
  • patients need to be rendered euthyroid before surgery
    • if thionamide antithyroid drugs cannot be used, treatment with iodine loading with potassium iodide, Lugol’s iodine, or oral cholecystographic contrast media (iopanoic acid 1 g daily) for 5-10 days will result in euthyroidism in almost all cases (1,2)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.